Cytotoxicity, Immunologic
"Cytotoxicity, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
| Descriptor ID |
D003602
|
| MeSH Number(s) |
G12.287
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cytotoxicity, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Cytotoxicity, Immunologic".
This graph shows the total number of publications written about "Cytotoxicity, Immunologic" by people in this website by year, and whether "Cytotoxicity, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 3 | 5 |
| 1995 | 0 | 5 | 5 |
| 1996 | 1 | 2 | 3 |
| 1997 | 3 | 5 | 8 |
| 1998 | 2 | 3 | 5 |
| 1999 | 2 | 3 | 5 |
| 2000 | 0 | 6 | 6 |
| 2001 | 2 | 8 | 10 |
| 2002 | 1 | 7 | 8 |
| 2003 | 2 | 5 | 7 |
| 2004 | 1 | 5 | 6 |
| 2005 | 1 | 5 | 6 |
| 2006 | 0 | 4 | 4 |
| 2007 | 1 | 3 | 4 |
| 2008 | 6 | 3 | 9 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 4 | 5 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 5 | 5 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytotoxicity, Immunologic" by people in Profiles.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation. Cytotherapy. 2020 08; 22(8):450-457.
-
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
-
Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med. 2019 04 10; 11(487).
-
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018 11 01; 24(21):5357-5367.
-
Unlocking the Complexities of Tumor-Associated Regulatory T Cells. J Immunol. 2018 01 15; 200(2):415-421.
-
The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer. Cancer Immunol Immunother. 2018 01; 67(1):13-23.
-
Transgenic expression of human leukocyte antigen-E attenuates GalKO.hCD46 porcine lung xenograft injury. Xenotransplantation. 2017 03; 24(2).
-
Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat Commun. 2016 08 17; 7:12499.
-
Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration. Mol Ther. 2016 09; 24(9):1665-74.